Full View

Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

WS Siegel-Lakhai, JH Beijnen, JHM Schellens - The oncologist, 2005 - academic.oup.com
The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …
被引用次数：155 相关文章
[PDF] psu.edu

[PDF][PDF] Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

WS Siegel-Lakhai, JH Beijnen, JHM Schellensa - The Oncologist, 2005 - Citeseer
Abstract Gefitinib (Iressa®; AstraZeneca Pharmaceuticals, Wilmington, DE, http://www.
astrazeneca-us. com) and erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY …

Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

WS Siegel-Lakhai, JH Beijnen, JHM Schellens - The Oncologist, 2005 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> The CME activity for this article is
forthcoming.</jats: p>< jats: p> Access and take the CME test online and receive 1 hour of …

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa)

WS Siegel-Lakhai, JH Beijnen… - The …, 2005 - pubmed.ncbi.nlm.nih.gov
Gefitinib (Iressa); AstraZeneca Pharmaceuticals, Wilmington, DE, http://www. astrazeneca-
us. com) and erlotinib (Tarceva); OSI Pharmaceuticals, Inc., Melville, NY, http://www. osip …
[PDF] wiley.com

[PDF][PDF] Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

WS Siegel‐Lakhai, JH Beijnen… - The Oncologist, 2005 - Wiley Online Library
Gefitinib (Iressa®; AstraZeneca Pharmaceuticals, Wilmington, DE, http://www. astrazeneca‐
us. com) and erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY, http://www. osip …

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

WS Siegel-Lakhai, JH Beijnen, JH Schellens - The Oncologist, 2005 - europepmc.org
Gefitinib (Iressa); AstraZeneca Pharmaceuticals, Wilmington, DE, http://www. astrazeneca-
us. com) and erlotinib (Tarceva); OSI Pharmaceuticals, Inc., Melville, NY, http://www. osip …

[引用][C] Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa)

SL WS - The Oncologist, 2005 - cir.nii.ac.jp
Current knowledge and future directions of the selective epidermal growth factor receptor
inhibitors erlotinib (Tarceva) and gefitinib (Iressa) | CiNii Research CiNii 国立情報学研究所 …
[PDF] psu.edu

[PDF][PDF] Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)

WS Siegel-Lakhai, JH Beijnen, JHM Schellensa - The Oncologist, 2005 - Citeseer
Abstract Gefitinib (Iressa®; AstraZeneca Pharmaceuticals, Wilmington, DE, http://www.
astrazeneca-us. com) and erlotinib (Tarceva®; OSI Pharmaceuticals, Inc., Melville, NY …

[引用][C] Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva®) and gefitinib (Iressa®)

WS SIEGEL-LAKHAI, JH BEIJNEN, JHM SCHELLENS - The Oncologist, 2005 - Alphamed